symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
GNLX,20.16,0,207129,527847264,0,5.35-40.98,-0.1,Genelux Corporation,USD,0001231457,,,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.genelux.com,"Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.",Mr. Thomas  Zindrick J.D.,Healthcare,US,20,858 483 0024,2625 Townsgate Road,Westlake Village,CA,91361,,0,https://financialmodelingprep.com/image-stock/GNLX.jpg,2023-01-26,False,False,True,False,False
